Literature DB >> 22033685

[Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].

H H Kreipe1.   

Abstract

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) represent neoplastic proliferations of hematopoietic stem cells, which may progress to loss of differentiation and acute myeloid leukemia (AML). Transitions between MDSs and MPNs as well as combinations between both disorders occur and MPNs may acquire dysplastic features combined with cytopenia. Myelodysplastic/myeloproliferative neoplasms show dysplastic and myeloproliferative properties and have in common genetic aberrations at the stem cell level (TET2, ASXL 1, CBL, IDH 1, IDH 2, EZH2, p53, Runx1), which may be found in one cell or may affect different hematopoietic stem cells, expanding in parallel. Progress to AML follows a linear clonal evolution only in a subset of cases. Alternatively AML derives from secondary clones, devoid of any marker mutation or originates from a common aberrant progenitor cell which shares other but not the JAK2 ( V617F ) mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033685     DOI: 10.1007/s00292-011-1504-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  10 in total

1.  Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach.

Authors:  P Foa; A Iurlo; G Saglio; A Guerrasio; F Capsoni; A T Maiolo
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

2.  Insights into JAK2-V617F mutation in CML.

Authors:  Guntram Büsche; Kais Hussein; Oliver Bock; Hans Kreipe
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

3.  Familial polycythemia vera with non-germline JAK2(V617F) mutation sparing the abnormal and clonal granulopoiesis.

Authors:  K Hussein; O Bock; M Ballmaier; G Göhring; D Steinemann; U Lehmann; J Kemper; T Buhr; H Kreipe
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

4.  Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.

Authors:  Kais Hussein; Oliver Bock; Katharina Theophile; Jerome Schlue; Matthias Ballmaier; Nicolaus Kröger; Gudrun Göhring; Guntram Büsche; Hans Kreipe
Journal:  Blood       Date:  2009-02-05       Impact factor: 22.113

Review 5.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

Review 6.  Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Authors:  Ayalew Tefferi; William Vainchenker
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 7.  Transition of polycythemia vera to chronic neutrophilic leukemia.

Authors:  T Higuchi; R Oba; M Endo; H Harada; H Mori; H Niikura; M Omine; K Fujita
Journal:  Leuk Lymphoma       Date:  1999-03

8.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors:  Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

9.  JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Authors:  Kais Hussein; Oliver Bock; Katharina Theophile; Nils von Neuhoff; Thomas Buhr; Jerome Schlué; Guntram Büsche; Hans Kreipe
Journal:  Exp Hematol       Date:  2009-07-17       Impact factor: 3.084

10.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.